Cover Image
市場調查報告書

激躁性結腸症:開發中產品分析

Irritable Bowel Syndrome - Pipeline Review, H1 2018

出版商 Global Markets Direct 商品編碼 232842
出版日期 內容資訊 英文 120 Pages
訂單完成後即時交付
價格
Back to Top
激躁性結腸症:開發中產品分析 Irritable Bowel Syndrome - Pipeline Review, H1 2018
出版日期: 2018年05月08日 內容資訊: 英文 120 Pages
簡介

激躁性結腸症(IBS)是伴隨慢性或復發性免疫反應的症狀,或是消化管發炎的用語。症候有腹部的痙攣和疼痛,有血的腹瀉,體重減輕,食慾不振,及發燒等。原因有年齡,家族病史,抽煙,止痛藥等。可使用皮質類固醇,免疫抑制劑,抗生素,鎮壓藥等來治療。

本報告提供全球各國治療激躁性結腸症(IBS)所用的開發中產品之開發情形相關分析,提供您產品開發·上市的最新趨勢,及臨床實驗的各階段產品一覽,主要企業簡介,主要藥物概要,最新的產業趨勢等資訊。

簡介

  • 調查範圍

激躁性結腸症概要

治療藥的開發

  • 開發中產品的概要
  • 各企業的開發平台
  • 大學/研究機關所開發的開發平台
  • 企業開發中的產品
  • 大學/研究機關開發中的產品

治療藥的評估

  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

激躁性結腸症的治療藥開發企業

  • 4D Pharma PLC
  • A. Menarini Industrie Farmaceutiche Riunite Srl
  • Alfa Wassermann SpA
  • Allergan Plc
  • Ardelyx Inc
  • Astellas Pharma Inc.
  • CJ HealthCare Corp
  • ConSynance Therapeutics Inc
  • Cosmo Pharmaceuticals NV
  • Dong-A ST Co., Ltd.
  • Eisai
  • Enterome Bioscience SA
  • GlaxoSmithKline Plc
  • Innovative Med Concepts LLC
  • Ironwood Pharmaceuticals Inc
  • Kissei藥品
  • Lexicon Pharmaceuticals Inc
  • Napo Pharmaceuticals Inc
  • Pfizer Inc
  • RaQualia Pharma Inc
  • RedHill Biopharma Ltd
  • SK Biopharmaceuticals Co Ltd
  • 大日本住友製藥
  • Synergy Pharmaceuticals Inc
  • Synthetic Biologics Inc
  • Vitality Biopharma Inc

藥物簡介

激躁性結腸症:暫停中的計劃

激躁性結腸症:開發中止的產品

激躁性結腸症:產品開發的里程碑

  • 主要消息和新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC10403IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Irritable Bowel Syndrome - Pipeline Review, H1 2018, provides an overview of the Irritable Bowel Syndrome (Gastrointestinal) pipeline landscape.

Irritable bowel syndrome (IBS) is a functional gastrointestinal disorder that affects large intestine (colon). Symptoms include cramping, abdominal pain, bloating gas, diarrhea, backache, muscle pains, poor appetite and constipation. These symptoms can be triggered by food, stress and hormones. Risk factors include age and family history. Treatment includes anti-diarrheal, anticholinergic, antidepressant and antibiotics medications.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Irritable Bowel Syndrome - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Irritable Bowel Syndrome (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Irritable Bowel Syndrome (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Irritable Bowel Syndrome and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 1, 9, 6, 1, 8 and 5 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 1 and 1 molecules, respectively.

Irritable Bowel Syndrome (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Irritable Bowel Syndrome (Gastrointestinal).
  • The pipeline guide reviews pipeline therapeutics for Irritable Bowel Syndrome (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Irritable Bowel Syndrome (Gastrointestinal) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Irritable Bowel Syndrome (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Irritable Bowel Syndrome (Gastrointestinal)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Irritable Bowel Syndrome (Gastrointestinal).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Irritable Bowel Syndrome (Gastrointestinal) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents 2
  • List of Tables 7
  • List of Figures 7
  • Introduction 9
  • Global Markets Direct Report Coverage 9
  • Irritable Bowel Syndrome - Overview 10
  • Irritable Bowel Syndrome - Therapeutics Development 11
  • Pipeline Overview 11
  • Pipeline by Companies 12
  • Pipeline by Universities/Institutes 15
  • Products under Development by Companies 16
  • Products under Development by Universities/Institutes 18
  • Irritable Bowel Syndrome - Therapeutics Assessment 19
  • Assessment by Target 19
  • Assessment by Mechanism of Action 21
  • Assessment by Route of Administration 23
  • Assessment by Molecule Type 24
  • Irritable Bowel Syndrome - Companies Involved in Therapeutics Development 26
  • 4D Pharma PLC 26
  • Allergan Plc 26
  • Ardelyx Inc 26
  • ConSynance Therapeutics Inc 27
  • Cosmo Pharmaceuticals NV 27
  • Dong-A ST Co Ltd 28
  • Eisai Co Ltd 28
  • Enterome Bioscience SA 29
  • GlaxoSmithKline Plc 29
  • ImmuneBiotech AB 29
  • Ironwood Pharmaceuticals Inc 30
  • Kissei Pharmaceutical Co Ltd 30
  • Metacrine Inc 31
  • Napo Pharmaceuticals Inc 31
  • RaQualia Pharma Inc 31
  • RedHill Biopharma Ltd 32
  • SK Biopharmaceuticals Co Ltd 32
  • Sumitomo Dainippon Pharma Co Ltd 33
  • Synthetic Biologics Inc 33
  • Vitality Biopharma Inc 34
  • Irritable Bowel Syndrome - Drug Profiles 35
  • BC-1261 - Drug Profile 35
  • Product Description 35
  • Mechanism Of Action 35
  • R&D Progress 35
  • bedoradrine sulfate - Drug Profile 36
  • Product Description 36
  • Mechanism Of Action 36
  • R&D Progress 36
  • Biologic for Irritable Bowel Syndrome with Constipation - Drug Profile 39
  • Product Description 39
  • Mechanism Of Action 39
  • R&D Progress 39
  • Biologic for Irritable Bowel Syndrome with Diarrhea - Drug Profile 40
  • Product Description 40
  • Mechanism Of Action 40
  • R&D Progress 40
  • Blautix - Drug Profile 41
  • Product Description 41
  • Mechanism Of Action 41
  • R&D Progress 41
  • Canchew Plus - Drug Profile 43
  • Product Description 43
  • Mechanism Of Action 43
  • R&D Progress 43
  • CIN-103 - Drug Profile 45
  • Product Description 45
  • Mechanism Of Action 45
  • R&D Progress 45
  • crofelemer DR - Drug Profile 46
  • Product Description 46
  • Mechanism Of Action 46
  • R&D Progress 46
  • CSTI-300 - Drug Profile 50
  • Product Description 50
  • Mechanism Of Action 50
  • R&D Progress 50
  • DA-6886 - Drug Profile 51
  • Product Description 51
  • Mechanism Of Action 51
  • R&D Progress 51
  • Drugs for Irritable Bowel Syndrome with Diarrhea - Drug Profile 52
  • Product Description 52
  • Mechanism Of Action 52
  • R&D Progress 52
  • DSP-6952 - Drug Profile 53
  • Product Description 53
  • Mechanism Of Action 53
  • R&D Progress 53
  • E-2508 - Drug Profile 54
  • Product Description 54
  • Mechanism Of Action 54
  • R&D Progress 54
  • EB-410 - Drug Profile 55
  • Product Description 55
  • Mechanism Of Action 55
  • R&D Progress 55
  • EB-420 - Drug Profile 56
  • Product Description 56
  • Mechanism Of Action 56
  • R&D Progress 56
  • GSK-3179106 - Drug Profile 57
  • Product Description 57
  • Mechanism Of Action 57
  • R&D Progress 57
  • IB-001 - Drug Profile 58
  • Product Description 58
  • Mechanism Of Action 58
  • R&D Progress 58
  • linaclotide - Drug Profile 59
  • Product Description 59
  • Mechanism Of Action 59
  • R&D Progress 59
  • linaclotide DR2 - Drug Profile 67
  • Product Description 67
  • Mechanism Of Action 67
  • R&D Progress 67
  • lovastatin MR - Drug Profile 68
  • Product Description 68
  • Mechanism Of Action 68
  • R&D Progress 68
  • LT-4006 - Drug Profile 72
  • Product Description 72
  • Mechanism Of Action 72
  • R&D Progress 72
  • ondansetron hydrochloride CR - Drug Profile 73
  • Product Description 73
  • Mechanism Of Action 73
  • R&D Progress 73
  • OP-687 - Drug Profile 82
  • Product Description 82
  • Mechanism Of Action 82
  • R&D Progress 82
  • ORP-101 - Drug Profile 83
  • Product Description 83
  • Mechanism Of Action 83
  • R&D Progress 83
  • PR-38 - Drug Profile 84
  • Product Description 84
  • Mechanism Of Action 84
  • R&D Progress 84
  • RDX-023 - Drug Profile 85
  • Product Description 85
  • Mechanism Of Action 85
  • R&D Progress 85
  • relenopride hydrochloride - Drug Profile 86
  • Product Description 86
  • Mechanism Of Action 86
  • R&D Progress 86
  • rifamycin CR - Drug Profile 88
  • Product Description 88
  • Mechanism Of Action 88
  • R&D Progress 88
  • RQ-00310941 - Drug Profile 92
  • Product Description 92
  • Mechanism Of Action 92
  • R&D Progress 92
  • Small Molecules to Inhibit TPH1 for Gastrointestinal, Metabolic Disorder and Oncology - Drug Profile 93
  • Product Description 93
  • Mechanism Of Action 93
  • R&D Progress 93
  • solabegron - Drug Profile 94
  • Product Description 94
  • Mechanism Of Action 94
  • R&D Progress 94
  • tenapanor - Drug Profile 97
  • Product Description 97
  • Mechanism Of Action 97
  • R&D Progress 97
  • VB-210 - Drug Profile 104
  • Product Description 104
  • Mechanism Of Action 104
  • R&D Progress 104
  • Irritable Bowel Syndrome - Dormant Projects 105
  • Irritable Bowel Syndrome - Discontinued Products 108
  • Irritable Bowel Syndrome - Product Development Milestones 109
  • Featured News & Press Releases 109
  • Apr 25, 2018: FDA Grants Fast Track Designation for OrphoMed's ORP-101 for Treatment of IBS-D 109
  • Apr 03, 2018: AXIM Biotech Reaches Preliminary Agreement for Distribution of CanChew Product Throughout South Korea 109
  • Mar 26, 2018: RedHill Biopharma Announces DDW 2018 Poster of Distinction on Positive Phase II Results with BEKINDA for IBS-D 109
  • Jan 17, 2018: Outpost Medicine Announces Acceptance of Two Investigational New Drug Applications for OP-687 by U.S. FDA 110
  • Jan 16, 2018: Sun Pharma Announces Settlement of Patent Litigation for Generic Linzess in US 110
  • Jan 16, 2018: RedHill Biopharma Announces Final Results from Phase II Study with BEKINDA for IBS-D 110
  • Jan 04, 2018: OrphoMed Appoints Gastroenterology Expert and Industry Veteran Mark Sostek, M.D. as Chief Medical Officer 111
  • Jan 03, 2018: Ardelyx Successfully Completes T3MPO-3 Safety Extension Study of Tenapanor for IBS-C 111
  • Dec 12, 2017: Cosmo Pharmaceuticals Announces First Patient Randomized In Its Proof Of Concept Phase II Clinical Trial Of Rifamycin SV In IBS-D 112
  • Oct 19, 2017: Jaguar Health Subsidiary Napo Pharmaceuticals Establishes Scientific Advisory Boards for Planned Follow-on Indications for Mytesi, Napo's FDA-approved Human Prescription Drug 112
  • Oct 16, 2017: Allergan to Present New Data on Gastrointestinal Drug Candidate Linaclotide at the World Congress of Gastroenterology at ACG 2017 113
  • Oct 16, 2017: Ardelyx Announces Tenapanor Reduces Pain Caused by IBS-C Through Inhibition of TRPV-1 Signaling 114
  • Oct 11, 2017: Ardelyxs Pivotal Phase 3 Study of Tenapanor for IBS-C Hits Primary and All Secondary Endpoints to Support NDA Submission in 2018 115
  • Oct 03, 2017: RedHill Biopharma Announces Positive Top-Line Results from Phase II Study of BEKINDA in Patients with IBS-D 116
  • Sep 28, 2017: RedHill Biopharma to Announce Top-Line Results from BEKINDA 12 mg Phase II Study for IBS-D on October 3rd, 2017 118
  • Appendix 119
  • Methodology 119
  • Coverage 119
  • Secondary Research 119
  • Primary Research 119
  • Expert Panel Validation 119
  • Contact Us 119
  • Disclaimer 120

List of Tables

  • Number of Products under Development for Irritable Bowel Syndrome, H1 2018 11
  • Number of Products under Development by Companies, H1 2018 13
  • Number of Products under Development by Companies, H1 2018 (Contd..1), H1 2018 14
  • Number of Products under Development by Universities/Institutes, H1 2018 15
  • Products under Development by Companies, H1 2018 16
  • Products under Development by Companies, H1 2018 (Contd..1), H1 2018 17
  • Products under Development by Universities/Institutes, H1 2018 18
  • Number of Products by Stage and Target, H1 2018 20
  • Number of Products by Stage and Mechanism of Action, H1 2018 22
  • Number of Products by Stage and Route of Administration, H1 2018 23
  • Number of Products by Stage and Molecule Type, H1 2018 25
  • Irritable Bowel Syndrome - Pipeline by 4D Pharma PLC, H1 2018 26
  • Irritable Bowel Syndrome - Pipeline by Allergan Plc, H1 2018 26
  • Irritable Bowel Syndrome - Pipeline by Ardelyx Inc, H1 2018 27
  • Irritable Bowel Syndrome - Pipeline by ConSynance Therapeutics Inc, H1 2018 27
  • Irritable Bowel Syndrome - Pipeline by Cosmo Pharmaceuticals NV, H1 2018 28
  • Irritable Bowel Syndrome - Pipeline by Dong-A ST Co Ltd, H1 2018 28
  • Irritable Bowel Syndrome - Pipeline by Eisai Co Ltd, H1 2018 28
  • Irritable Bowel Syndrome - Pipeline by Enterome Bioscience SA, H1 2018 29
  • Irritable Bowel Syndrome - Pipeline by GlaxoSmithKline Plc, H1 2018 29
  • Irritable Bowel Syndrome - Pipeline by ImmuneBiotech AB, H1 2018 30
  • Irritable Bowel Syndrome - Pipeline by Ironwood Pharmaceuticals Inc, H1 2018 30
  • Irritable Bowel Syndrome - Pipeline by Kissei Pharmaceutical Co Ltd, H1 2018 31
  • Irritable Bowel Syndrome - Pipeline by Metacrine Inc, H1 2018 31
  • Irritable Bowel Syndrome - Pipeline by Napo Pharmaceuticals Inc, H1 2018 31
  • Irritable Bowel Syndrome - Pipeline by RaQualia Pharma Inc, H1 2018 32
  • Irritable Bowel Syndrome - Pipeline by RedHill Biopharma Ltd, H1 2018 32
  • Irritable Bowel Syndrome - Pipeline by SK Biopharmaceuticals Co Ltd, H1 2018 33
  • Irritable Bowel Syndrome - Pipeline by Sumitomo Dainippon Pharma Co Ltd, H1 2018 33
  • Irritable Bowel Syndrome - Pipeline by Synthetic Biologics Inc, H1 2018 34
  • Irritable Bowel Syndrome - Pipeline by Vitality Biopharma Inc, H1 2018 34
  • Irritable Bowel Syndrome - Dormant Projects, H1 2018 105
  • Irritable Bowel Syndrome - Dormant Projects, H1 2018 (Contd..1), H1 2018 106
  • Irritable Bowel Syndrome - Dormant Projects, H1 2018 (Contd..2), H1 2018 107
  • Irritable Bowel Syndrome - Discontinued Products, H1 2018 108

List of Figures

  • Number of Products under Development for Irritable Bowel Syndrome, H1 2018 11
  • Number of Products under Development by Companies, H1 2018 12
  • Number of Products under Development by Universities/Institutes, H1 2018 15
  • Number of Products by Top 10 Targets, H1 2018 19
  • Number of Products by Stage and Top 10 Targets, H1 2018 19
  • Number of Products by Top 10 Mechanism of Actions, H1 2018 21
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2018 21
  • Number of Products by Stage and Routes of Administration, H1 2018 23
  • Number of Products by Molecule Types, H1 2018 24
  • Number of Products by Stage and Molecule Types, H1 2018 24
Back to Top